Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This should be treated as a long term investment in my view. Significant Shareholder value should be realised as drugs progress through the pipeline. Look at HCM, its a £3bn mcap Company and is still loss making. 10 years ago it was a £166m mcap Company with a smaller and earlier stage pipeline than Tiziana's is today.
Yes, VERY frustrating, I think the ATMs.
That said, I think this is why Gabriele prefers to be on Nas not Aim as they value pharma shares higher
But can you rationally explain why it's now impossible to sell even a tiny amount for 103p?
One great RNS after another and stuck in this range still? Can't blame the MMs, it's the sellers but who and why? Seems at the moment it doesn't matter what the news is, it will be sold into any rise. Frustrating!
I nearly top sliced to get into PHE yesterday at 2.5p, wish I had now, as we seem to be flat for a bit at the moment, even with all the good news.....frustrating to say the least
Hi Frag, One potential bonus could be that TILS sells STEM for cash and distributes the cash to shareholders but retains some cash to ensure no future need for TILS to raise cash.
Agreed. The US market will love this!
Watch later on
As an experienced Investor in U.S. Biotech I'm confident that the U.S. Investor community who are aware of #tils will like this - especially the move into Phase 2 eg. a move from dose finding and safety in healthy humans to a full trial in patients
As an experienced Investor in U.S. Biotech I'm confident that the U.S. Investor community who are aware of #tils will like this - especially the move into Phase 2 eg. a move from dose finding and safety in healthy humans to a full trial in patients
100% yes. But DYOR.
Only time before this multibags
Worth trying to get in before resistance is broken?